Medicare Part D Rebates Reconciliation: Which Report Changes the Plan’s Payment?

Medicare Part D rebates reconciliation connects the rebates a plan or its pharmacy benefit manager receives to the net drug costs used to settle Medicare’s payments. The manufacturer contract says what the rebate buys. The accounting shows who kept it. The report to the Centers for Medicare & Medicaid Services determines whether the government gets the benefit of that concession. If you work with those records, you may know where the money changed categories before it reached the report.

When the Rebate Changed Names

Rite Aid and Elixir Insurance agreed in July 2024 to a $101 million payment to the United States to resolve allegations about how manufacturer rebates were reported. The alleged conduct concerned 2014 through 2020, well before the benefit redesign.

The Justice Department alleged that portions of retained rebates were reported to the Centers for Medicare & Medicaid Services as bona fide service fees even though manufacturers had not negotiated to pay those fees. It also alleged that Elixir knew the retained rebates did not qualify for that treatment. A former employee of RX Options brought the whistleblower case.

The manufacturer paid a rebate. Medicare was supposed to get the benefit. According to the government, changing the label kept part of that benefit from Medicare. The service agreement and the reporting decision are where the accounting question becomes a whistleblower’s evidence.

Which Payment Does the Reconciliation Change?

Reconciliation can settle a plan’s payment from Medicare, a manufacturer’s inflation-rebate bill, or a private rebate agreement. Each calculation has its own payer, period and inputs. Calling all of them rebate reconciliation conceals the question that matters: whose payment changed?

The Plan’s Payment From Medicare

The Centers for Medicare & Medicaid Services reconciles plan payments after the year ends using actual enrollment, risk factors and allowable drug costs after rebates and other discounts.

A rebate retained by a pharmacy benefit manager still matters. The Part D definition of direct and indirect remuneration reaches price concessions obtained by an intermediary even when it keeps some or all of the money. The private agreement about who gets the rebate and the government’s treatment of that rebate are separate questions.

The Manufacturer’s Inflation-Rebate Bill

The Medicare Part D Drug Inflation Rebate Program requires manufacturers to pay rebates on certain drugs whose prices rise faster than inflation. Its annual measurement period begins October 1. The agency calculates the manufacturer’s obligation from price and utilization data, then issues a Rebate Report that serves as the invoice.

The preliminary report identifies the drug, units dispensed, benchmark price, annual manufacturer price, inflation adjustment and any reductions. These are the inputs behind the bill.

The agency reconciles the bill later, and updated prices or units can change what the manufacturer owes. If manufacturer misreporting made the calculation inaccurate, the agency can redo the bill at any time.

The Private Rebate Settlement

A private reconciliation compares what the contract promises with the claims, rebates earned and money paid or credited. Its definitions can reach manufacturer payments described as administrative fees or data fees as well as rebates. Its reporting and audit terms determine how much of that calculation the customer can see.

That contract settlement supplies part of the financial history behind a plan’s reported costs. The government’s annual payment calculation asks what belongs in Medicare’s calculation, including concessions an intermediary retained.

How the Part D Money Moves

Part D runs through private plans that submit annual bids and negotiate drug prices themselves or through pharmacy benefit managers. Medicare pays a direct subsidy adjusted for risk and provides reinsurance toward high drug costs. Risk corridors share gains and losses between Medicare and the plan. Beneficiaries contribute premiums and cost sharing, while manufacturers contribute negotiated rebates and required discounts.

The bid looks forward. Reconciliation looks back at what actually happened. A report that overstates allowable net drug costs changes the basis on which Medicare settles its bill with the plan.

The prices within that chain answer different questions. A manufacturer’s list price is its published price. The pharmacy’s negotiated price governs the dispensing transaction. Net drug cost reflects rebates and other concessions. A large concession arriving later can lower the plan’s cost while leaving the patient exposed to the earlier pharmacy price.

Do Pharmacy Benefit Managers Have a Role in the Prescription Drug Supply Chain?

Pharmacy benefit managers negotiate prices and access between manufacturers, plans and pharmacies. Their formularies help determine which drugs a plan covers and on what terms. The plan’s charge, the pharmacy’s payment and the manufacturer’s rebate therefore belong beside one another when we examine the money.

The Part D payment rules specifically classify the difference between what a plan pays an intermediary and what the intermediary pays the dispensing pharmacy as an administrative cost. This spread affects the intermediary’s earnings, but reinsurance and risk corridors operate on drug costs. Moving an amount between those categories can change the payment calculation.

What Changed in 2024 and 2025?

The pharmacy price changed in 2024. The benefit’s division of costs changed in 2025. An older rebate or dispensing record belongs to the rules for its own period, even when the accounting work continues later.

Pharmacy Concessions Reached the Point of Sale

From January 1, 2024, the negotiated price became the lowest possible reimbursement the network pharmacy would receive for the drug, including dispensing fees and all pharmacy price concessions. Additional contingent amounts that increase the price, such as incentive payments, are excluded. Non-pharmacy concessions reduce that price when the sponsor passes them through at the point of sale.

Before 2024, a pharmacy concession that depended on a later performance measurement could stay out of the price at the counter. A later performance fee could reduce what the pharmacy kept after the patient had already paid coinsurance on the higher amount. The pricing change brought that pharmacy concession into the earlier calculation.

The difference matters to an insider holding a pharmacy settlement statement. The concession’s source, the dispensing date and its treatment at the counter explain where it belongs in the accounting.

Plans Took More of the Catastrophic Cost

Beneficiary cost sharing in the catastrophic phase ended in 2024. In 2025, the standard benefit eliminated the separate coverage-gap phase and introduced an annual out-of-pocket cap of $2,000. The cap rose to $2,100 for 2026.

Under the standard 2025 design, the plan typically pays 60% in the catastrophic phase. For drugs covered by the Manufacturer Discount Program, the manufacturer’s typical share is 20% and federal reinsurance is 20%. For other covered drugs, federal reinsurance is 40%. That replaces a structure in which federal reinsurance covered 80% of catastrophic costs. The plan now carries much more of the expensive prescription.

Older Coverage-Gap Bills Survived

The Coverage Gap Discount Program stopped applying to drugs dispensed on or after January 1, 2025. It continues to apply to earlier dispensings. Replacing the program did not erase those obligations.

For applicable brand drugs in the gap during 2019 through 2024, the manufacturer discount was 70%. That discount counted toward the beneficiary’s out-of-pocket threshold even though the beneficiary had not paid it. The old threshold and the patient’s own cash spending therefore measured different things.

The replacement Manufacturer Discount Program extends beyond the old gap and includes low-income subsidy beneficiaries, whom the old discount program excluded. A reconciliation spanning the change needs the dispensing date, drug and beneficiary category to identify the obligation.

What the Contract and the Claim Can Show

The contract identifies the payment promised. The claim identifies the drug and transaction to which it belongs. Rebate reports and accounting records connect what was earned to what was allocated and paid. We compare those records with the treatment in the government’s payment calculation.

Sandia National Laboratories’ pharmacy benefit manager procurement statement, for services beginning in 2013, shows how specific those records can be. It defined rebates to include formulary and market-share rebates and related administrative or data fees attributable to its members’ prescriptions. Its pass-through proposal required pharmacy rates to pass through claim by claim, with no spread.

The statement required quarterly rebate reports with claim counts and a full annual reconciliation. Audit rights reached paid claims, reporting to manufacturers, accounting for earned rebates and allocating payments to Sandia. These were terms for Sandia’s self-insured medical plans. They give a concrete example of the records behind a private reconciliation.

For inflation rebates, the government rule supplies another precise connection. The Centers for Medicare & Medicaid Services uses the quantity dispensed on prescription drug event records to count covered units, matches the drug identifier and converts units when the manufacturer’s reporting uses a different unit type. A changed quantity or unit mapping can therefore change the manufacturer’s bill.

The exclusion of units discounted under the 340B program is dated too. For the period beginning October 1, 2025, it applies to claims with service dates on or after January 1, 2026. For periods beginning October 1, 2026, onward, the exclusion applies throughout the period. The reconciliation uses updated unit information as well as restated prices.

What the Other Reports Changed

The AstraZeneca and Medco cases show why a rebate review has to follow what the concession bought, as well as how it was reported. In its 2015 AstraZeneca settlement announcement, the Justice Department alleged that concessions on Prilosec, Toprol XL and Plendil bought Nexium’s sole and exclusive formulary position. The resulting claims concerned the Retiree Drug Subsidy Program. Medco later reached a separate settlement over its side of the arrangement.

The products carrying the discounts and the product receiving the preferred position were different. Following only the favored drug’s rebate ledger would miss the alleged exchange.

The Price Report Can Reach the Patient First

RxAmerica, a CVS subsidiary, reached a $5.25 million civil settlement in 2012 over allegations that it submitted inaccurate drug prices to the Centers for Medicare & Medicaid Services for Medicare Plan Finder, affecting beneficiaries’ plan choices. Here the disputed report reached the enrollment decision. The report’s audience and use explain the alleged harm.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We work with insiders to connect the payment, the report and the decisions behind it.

Why a Larger Rebate Can Leave the Patient Paying More

A rebate can reduce the plan’s eventual net cost while the patient’s coinsurance remains tied to a higher pharmacy price. In the Government Accountability Office’s analysis of categorized Part D rebates, 92.7% of categorized rebate dollars in 2021 were associated with formulary access and tier placement. The money largely bought a position on the plan’s list.

The size of that concession varies sharply. The Medicare Payment Advisory Commission’s 2024 therapeutic-class data put postsale rebates below 10% of gross spending in some classes and at 50% or more in others. An overall rebate rate tells an insider little about the particular drug being reconciled.

The USC Schaeffer Center’s 2020 white paper, The Association Between Drug Rebates and List Prices, examined U.S. brand-drug prices from 2015 through 2018 and found that increases in estimated rebates tracked increases in list prices. It also found an important difference between drugs facing generic competition and those without it:

The study’s estimated rebates included concessions across the supply chain. Its finding helps explain why a larger rebate and higher patient health care costs can travel together. The insider’s contract and reports show who received the concession in a particular arrangement.

When You Know Where the Rebate Went

If you work in plan finance, rebate operations or pharmacy contracting and know why the money received differs from the amount reported, talk with our whistleblower experts about that difference. We build your healthcare fraud case with you around the contracts, the reporting choices and the government payment they changed. We bring in Medicare Part D whistleblower lawyers who understand rebate reporting, and we stay your partners throughout.